Trial
NCT03437200
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Inoperable œsophageal Cancer
Intervention
Nivolumab
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-21